Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemafibrate therapy for hyperlipidemia with chronic kidney disease, including dialysis patients
jRCT1041240077Recruiting
- Sponsor
- Kowa Company, Ltd.
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of pemafibrate in chronic kidney disease (CKD), hypertriglyceridemia and hyperlipidemia, sponsored by Kowa Company, Ltd. Primary endpoint: Percentage of TG concentrations achieving <150 mg/dL at 24 weeks. Started Aug 2024; status: recruiting.
02
Drugs
pemafibrate
03
Conditions
chronic kidney disease (CKD)hypertriglyceridemiahyperlipidemia
Beyond the preview
Go deeper on jRCT1041240077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1041240077.